13.02
price up icon3.25%   0.41
after-market After Hours: 13.02
loading
Edgewise Therapeutics Inc stock is traded at $13.02, with a volume of 582.67K. It is up +3.25% in the last 24 hours and down -14.57% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$12.61
Open:
$12.67
24h Volume:
582.67K
Relative Volume:
0.36
Market Cap:
$1.63B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-8.4174
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
+1.56%
1M Performance:
-14.57%
6M Performance:
-48.78%
1Y Performance:
-37.76%
1-Day Range:
Value
$12.67
$13.14
1-Week Range:
Value
$12.51
$13.37
52-Week Range:
Value
$10.60
$38.12

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name
Name
Edgewise Therapeutics Inc
Name
Phone
720-262-7002
Name
Address
1715 38TH ST, BOULDER
Name
Employee
117
Name
Twitter
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
EWTX's Discussions on Twitter

Compare EWTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
EWTX
Edgewise Therapeutics Inc
13.02 1.63B 0 -115.88M -104.72M -1.5468
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
466.36 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.75 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
317.50 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
538.64 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.47 28.51B 3.81B -644.79M -669.77M -6.24

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-30-25 Initiated Guggenheim Buy
Apr-02-25 Downgrade Scotiabank Sector Outperform → Sector Perform
Mar-07-25 Initiated Scotiabank Sector Outperform
Jan-22-25 Initiated Stifel Hold
Nov-22-24 Initiated Evercore ISI Outperform
Mar-07-24 Initiated Piper Sandler Overweight
May-01-23 Initiated Truist Buy
Aug-25-22 Downgrade Goldman Neutral → Sell
Apr-13-22 Initiated RBC Capital Mkts Outperform
Jan-28-22 Initiated Goldman Neutral
View All

Edgewise Therapeutics Inc Stock (EWTX) Latest News

pulisher
Jun 18, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.8%Here's What Happened - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stake Boosted by GAMMA Investing LLC - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

Rhumbline Advisers Purchases 6,440 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World

Jun 17, 2025
pulisher
Jun 14, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $39.78 Average PT from Analysts - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Enliven to sell $200M in stock after positive drug trial - BizWest

Jun 13, 2025
pulisher
Jun 10, 2025

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Edgewise Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 03 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Bank of America Corp DE Has $1.31 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Edgewise Therapeutics (NASDAQ:EWTX) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat

Jun 08, 2025
pulisher
Jun 07, 2025

Ameriprise Financial Inc. Purchases Shares of 22,584 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

Royal Bank of Canada Reaffirms Outperform Rating for Edgewise Therapeutics (NASDAQ:EWTX) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Decreases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Edgewise Therapeutics (EWTX) Receives Reaffirmed 'Outperform' Ra - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

RBC Capital maintains outperform rating on Edgewise Therapeutics stock By Investing.com - Investing.com India

Jun 05, 2025
pulisher
Jun 05, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Universal Beteiligungs und Servicegesellschaft mbH Invests $2.40 Million in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference - Eastern Progress

Jun 04, 2025
pulisher
Jun 03, 2025

Muscle Disease Leader Edgewise Therapeutics Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan

Jun 03, 2025
pulisher
Jun 02, 2025

Two Sigma Investments LP Has $3.52 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

Jun 02, 2025
pulisher
Jun 01, 2025

Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Certain Common Stock of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

(EWTX) Technical Data - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by Nuveen Asset Management LLC - MarketBeat

Jun 01, 2025
pulisher
May 31, 2025

Polar Asset Management Partners Inc. Has $1.72 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 31, 2025
pulisher
May 29, 2025

Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Acquires 158,452 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Woodline Partners LP Has $15.15 Million Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 27, 2025
pulisher
May 27, 2025

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 174% Potential Upside in Biotech - DirectorsTalk Interviews

May 27, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Makes New $883,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 27, 2025
pulisher
May 26, 2025

106,562 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Purchased by Point72 Asset Management L.P. - MarketBeat

May 26, 2025
pulisher
May 25, 2025

Frazier Life Sciences Management L.P. Cuts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges By Investing.com - Investing.com South Africa

May 24, 2025
pulisher
May 24, 2025

Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges - Investing.com India

May 24, 2025
pulisher
May 23, 2025

Polar Asset Management Partners Inc. Trims Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 23, 2025
pulisher
May 23, 2025

Tang Capital Management LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Deutsche Bank AG Grows Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat

May 22, 2025
pulisher
May 22, 2025

How to Take Advantage of moves in (EWTX) - news.stocktradersdaily.com

May 22, 2025

Edgewise Therapeutics Inc Stock (EWTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Edgewise Therapeutics Inc Stock (EWTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Russell Alan J
Chief Scientific Officer
May 02 '25
Sale
16.45
1,551
25,520
18,521
MOORE JOHN R
General Counsel
May 01 '25
Option Exercise
0.00
5,209
0
8,461
MOORE JOHN R
General Counsel
May 02 '25
Sale
16.45
1,930
31,757
6,531
KOCH KEVIN
President and CEO
May 01 '25
Option Exercise
0.00
10,417
0
24,895
KOCH KEVIN
President and CEO
May 02 '25
Sale
16.45
4,276
70,358
20,619
Donovan Joanne M.
CMO
May 01 '25
Option Exercise
0.00
10,417
0
26,775
Donovan Joanne M.
CMO
May 02 '25
Sale
16.45
5,187
85,348
21,588
Derakhshan Behrad
Chief Business Officer
May 01 '25
Option Exercise
0.00
5,209
0
22,046
Derakhshan Behrad
Chief Business Officer
May 02 '25
Sale
16.45
1,691
27,824
20,355
Carruthers R Michael
Chief Financial Officer
May 01 '25
Option Exercise
0.00
5,209
0
82,328
$21.25
price up icon 3.56%
$35.51
price down icon 0.22%
$22.99
price up icon 1.68%
$96.14
price down icon 0.84%
$111.66
price up icon 1.46%
biotechnology ONC
$244.47
price up icon 1.44%
Cap:     |  Volume (24h):